Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program
暂无分享,去创建一个
Lee H. Harrison | David W. Warnock | G. Lyon | L. Harrison | M. Brandt | R. Hajjeh | A. Sofair | B. Arthington-Skaggs | D. Warnock | W. Lee-Yang | M. Ciblak | M. Phelan | S. Mirza | Maureen Phelan | Juliette Morgan | Rana A. Hajjeh | Mary E. Brandt | Andre N. Sofair | G. Marshall Lyon | Beth A. Arthington-Skaggs | Sara A. Mirza | Wendy Lee-Yang | Meral A. Ciblak | Lynette E. Benjamin | Laurie Thomson Sanza | Sharon Huie | Siew Fah Yeo | S. Huie | J. Morgan | L. Benjamin | S. Yeo | Laurie Thomson Sanza | Wendy Lee-Yang
[1] M. Brandt,et al. Resolution of Discrepant Results for Candida Species Identification by Using DNA Probes , 2004, Journal of Clinical Microbiology.
[2] Shane Gillespie,et al. Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] M. Pfaller,et al. In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods , 2002, Antimicrobial Agents and Chemotherapy.
[4] D. Pittet,et al. Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital , 2002, Medicine.
[5] J. Pemán,et al. Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for Death , 2002, European Journal of Clinical Microbiology and Infectious Diseases.
[6] J. Rex,et al. Has antifungal susceptibility testing come of age? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Pfaller,et al. Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.
[8] R. Gaynes,et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] A. Tortorano,et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. , 2002, The Journal of hospital infection.
[10] H. Richet,et al. Candidemia in French hospitals: incidence rates and characteristics. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[11] M. Pfaller,et al. Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study , 2002, Journal of Clinical Microbiology.
[12] D. Kontoyiannis,et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. , 2002, The American journal of medicine.
[13] M. Pfaller,et al. Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000 , 2002, Journal of Clinical Microbiology.
[14] D. Sanglard,et al. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. , 2002, The Lancet. Infectious diseases.
[15] D. Kaufman,et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. , 2001, The New England journal of medicine.
[16] M. Pfaller,et al. International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.
[17] J. Sobel,et al. Invasive candidiasis: turning risk into a practical prevention policy? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] M. Romagnoli,et al. Evaluation of a Reformulated CHROMagar Candida , 2001, Journal of Clinical Microbiology.
[19] A. Freydiere,et al. Yeast identification in the clinical microbiology laboratory: phenotypical methods. , 2001, Medical mycology.
[20] A. Favel,et al. Improved Detection of Amphotericin B-Resistant Isolates of Candida lusitaniae by Etest , 2001, Journal of Clinical Microbiology.
[21] L. Saiman,et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients , 2000, The Pediatric infectious disease journal.
[22] Albert Balows,et al. Manual of Clinical Microbiology, 7th ed. , 2000 .
[23] R. Pinner,et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] D. McClish,et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] B. Lebeau,et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] C. Clancy,et al. Correlation between In Vitro Susceptibility Determined by E Test and Response to Therapy with Amphotericin B: Results from a Multicenter Prospective Study of Candidemia , 1999, Antimicrobial Agents and Chemotherapy.
[27] A. Bolmström,et al. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. , 1998, Diagnostic microbiology and infectious disease.
[28] P Bacchetti,et al. Risk of Low Birth Weight Infants Among Black and White Parents , 1998, Obstetrics and gynecology.
[29] T. Lott,et al. Rapid Identification of Candida Species with Species-Specific DNA Probes , 1998, Journal of Clinical Microbiology.
[30] R. Salomão,et al. Risk Factors for Death in Patients With Candidemia , 1998, Infection Control & Hospital Epidemiology.
[31] M. Halpern,et al. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] M. A. Martin,et al. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. , 1998, Diagnostic microbiology and infectious disease.
[33] Ronald N. Jones,et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. , 1998, Diagnostic microbiology and infectious disease.
[34] M. White. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] E. Anaissie,et al. The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] D. Snydman,et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.
[37] J. Rex,et al. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates , 1995, Antimicrobial agents and chemotherapy.
[38] M. Levenstein,et al. A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .
[39] M. Larocco,et al. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period , 1994, Antimicrobial Agents and Chemotherapy.
[40] J. Weems. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] W J Martone,et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.
[42] R. Woolson,et al. Risk factors for hospital-acquired candidemia. A matched case-control study. , 1989, Archives of internal medicine.
[43] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[44] Ellen Jo Baron,et al. Manual of clinical microbiology , 1975 .
[45] Patrick R. Murray,et al. Candida, Cryptococcus, and other yeasts of medical importance. , 2006 .
[46] J. Latgé,et al. Aspergillus fumigatus cell wall: composition and biosynthesis. , 2001, Medical mycology.
[47] L. Harrison,et al. Candida dubliniensis fungemia: the first four cases in North America. , 2000, Emerging infectious diseases.
[48] T. C. White,et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.
[49] J. Wingard,et al. Importance of Candida species other than C. albicans as pathogens in oncology patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.